Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693565 | 0.84 | MAPT (0.59) | MAPTALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL11771726 | 0.72 | KDM4E (0.50) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1677978 | 0.72 | RAB9A (0.38) | MAPTALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL650259 | 0.70 | NPC1 (0.51) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL7142078 | 0.70 | NPC1 (0.51) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1180215 | 0.70 | MAPT (0.84) | MAPTALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7253210 | 0.69 | CYP19A1 (0.72) | MAPTALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL17279819 | 0.69 | NPC1 (0.50) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL10752291 | 0.68 | CYP19A1 (0.60) | MAPTALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3685934 | 0.68 | TAAR1 (0.55) | MAPTALDH1A1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921077-B1 | AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-26 | — | — | EP | disclosed |
| US-7928098-B2 | Therapeutic and/or preventive agents for a sleep disorder | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20100280023-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-1921077-A1 | AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1894930-A1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | HCRTR1, MTNR1A, HCRTR2 | MAPT 2204/4885ALDH1A1 638/4885RAB9A 1949/4885 |
| US-20100280023-A1 | THIAZOLE DERIVATIVES | ADORA2A, ADORA3, GPR6 | MAPT 3668/4885ALDH1A1 1449/4885RAB9A 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.